{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:17:14Z","timestamp":1795047434435,"version":"4.10.2"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2018 Entrepreneurial Leading Talent of Guangzhou Huangpu District and Guangzhou Development District","award":["2022-L023"],"award-info":[{"award-number":["2022-L023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer is one of the most common cancers in men with notable interpatient heterogeneity. Implications of the immune microenvironment in predicting the biochemical recurrence-free survival (BCRFS) after radical prostatectomy and the efficacy of systemic therapies in prostate cancer remain ambiguous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The tumor immune contexture score (TICS) involving eight immune contexture-related signatures was developed using seven cohorts of 1120 patients treated with radical prostatectomy (training: GSE46602, GSE54460, GSE70769, and GSE94767; validation: GSE70768, DKFZ2018, and TCGA). The association between the TICS and treatment efficacy was investigated in GSE111177 (androgen deprivation therapy [ADT]) and EGAS00001004050 (ipilimumab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A high TICS was associated with prolonged BCRFS after radical prostatectomy in the training (HR\u2009=\u20090.32, 95% CI 0.24\u20130.45,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and the validation cohorts (HR\u2009=\u20090.45, 95% CI 0.32\u20130.62,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The TICS showed stable prognostic power independent of tumor stage, surgical margin, pre-treatment prostatic specific antigen (PSA), and Gleason score (multivariable HR\u2009=\u20090.50, 95% CI 0.39\u20130.63,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Adding the TICS into the prognostic model constructed using clinicopathological features significantly improved its 1\/2\/3\/4\/5-year area under curve (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). A low TICS was associated with high homologous recombination deficiency scores, abnormally activated pathways concerning DNA replication, cell cycle, steroid hormone biosynthesis, and drug metabolism, and fewer tumor-infiltrating immune cells (P\u2009&lt;\u20090.05). The patients with a high TICS had favorable BCRFS with ADT (HR\u2009=\u20090.25, 95% CI 0.06\u20130.99,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034) or ipilimumab monotherapy (HR\u2009=\u20090.23, 95% CI 0.06\u20130.81,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study delineates the associations of tumor immune contexture with molecular features, recurrence after radical prostatectomy, and the efficacy of ADT and immunotherapy. The TICS may improve the existing risk stratification systems and serve as a patient-selection tool for ADT and immunotherapy in prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-022-03827-4","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T04:03:18Z","timestamp":1678766598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Sujun","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"3827_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3827_CR2","first-page":"1552","volume":"58","author":"C Dubost","year":"1965","unstructured":"Dubost C, Blondeau P, d\u2019Allaines C, Piwnica A, Guilmet D. Surgical treatment of tetralogy of fallot. (Complete correction under extracorporeal circulation). Arch Mal Coeur Vaiss. 1965;58:1552\u201363.","journal-title":"Arch Mal Coeur Vaiss"},{"key":"3827_CR3","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1021\/mp500099g","volume":"11","author":"F Li","year":"2014","unstructured":"Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm. 2014;11:2539\u201352. https:\/\/doi.org\/10.1021\/mp500099g","journal-title":"Mol Pharm"},{"key":"3827_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3389\/fonc.2019.00858","volume":"9","author":"Q Feng","year":"2019","unstructured":"Feng Q, He B. Androgen receptor signaling in the development of castration-resistant prostate cancer. Front Oncol. 2019;9:858.","journal-title":"Front Oncol"},{"key":"3827_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-030-83282-7_4","volume":"1350","author":"JW Freeman","year":"2021","unstructured":"Freeman JW. Structural biology of the tumor microenvironment. Adv Exp Med Biol. 2021;1350:91\u2013100.","journal-title":"Adv Exp Med Biol"},{"key":"3827_CR6","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557\u201366.","journal-title":"Cancer Res"},{"key":"3827_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/08923970802380452","volume":"31","author":"O Molavi","year":"2009","unstructured":"Molavi O, Ma Z, Hamdy S, Lavasanifar A, Samuel J. Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124. Immunopharmacol Immunotoxicol. 2009;31:214\u201321.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"3827_CR8","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1007\/s00018-020-03459-1","volume":"77","author":"S Jafari","year":"2020","unstructured":"Jafari S, Molavi O, Kahroba H, Hejazi MS, Maleki-Dizaji N, Barghi S, et al. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell Mol Life Sci. 2020;77:3693\u2013710.","journal-title":"Cell Mol Life Sci"},{"key":"3827_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1600-0463.2012.02924.x","volume":"120","author":"A Flammiger","year":"2012","unstructured":"Flammiger A, Bayer F, Cirugeda-K\u00fchnert A, Huland H, Tennstedt P, Simon R, et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012;120:901\u20138.","journal-title":"APMIS"},{"key":"3827_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/sj.bjc.6601943","volume":"91","author":"PA McArdle","year":"2004","unstructured":"McArdle PA, Canna K, McMillan DC, McNicol AH, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91:541\u20133.","journal-title":"Br J Cancer"},{"key":"3827_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","volume":"54","author":"KL Knutson","year":"2005","unstructured":"Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54:721\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"3827_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-0716-0266-9_8","volume":"2111","author":"W Yang","year":"2020","unstructured":"Yang W, Chen X, Hu H. CD4+ T-cell differentiation in vitro. Methods Mol Biol. 2020;2111:91\u20139.","journal-title":"Methods Mol Biol"},{"key":"3827_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE. Differentiation of effector CD4+ T cell populations. Annu Rev Immunol. 2010;28:445\u201389.","journal-title":"Annu Rev Immunol"},{"key":"3827_CR14","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-07-5164","volume":"14","author":"KS Sfanos","year":"2008","unstructured":"Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, Demarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals T H17 and Treg skewing. Clin Cancer Res. 2008;14:3254\u201361.","journal-title":"Clin Cancer Res"},{"key":"3827_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/pros.23343","volume":"77","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Liu S, Ge D, Cunningham DM, Huang F, Ma L, et al. Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model. Prostate. 2017;77:888\u201399.","journal-title":"Prostate"},{"key":"3827_CR16","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020\u201331.","journal-title":"N Engl J Med"},{"key":"3827_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/17512433.2018.1464388","volume":"11","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho P, Antonarakis ES. PD-1\/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11:475\u201386.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3827_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395.","journal-title":"J Clin Oncol"},{"key":"3827_CR19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fbioe.2020.00930","volume":"8","author":"Z Gao","year":"2020","unstructured":"Gao Z, Tao Y, Lai Y, Wang Q, Li Z, Peng S, et al. Immune cytolytic activity as an indicator of immune checkpoint inhibitors treatment for prostate cancer. Front Bioeng Biotechnol. 2020;8:930.","journal-title":"Front Bioeng Biotechnol"},{"key":"3827_CR20","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/srep16018","volume":"5","author":"MM Mortensen","year":"2015","unstructured":"Mortensen MM, H\u00f8yer S, Lynnerup AS, \u00d8rntoft TF, S\u00f8rensen KD, Borre M, et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015;5:16018.","journal-title":"Sci Rep"},{"key":"3827_CR21","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-13-2699","volume":"74","author":"Q Long","year":"2014","unstructured":"Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;74:3228\u201337.","journal-title":"Cancer Res"},{"key":"3827_CR22","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.ebiom.2015.07.017","volume":"2","author":"H Ross-Adams","year":"2015","unstructured":"Ross-Adams H, Lamb A, Dunning M, Halim S, Lindberg J, Massie C, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine. 2015;2:1133\u201344.","journal-title":"EBioMedicine"},{"key":"3827_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.euf.2017.01.016","volume":"4","author":"BA Luca","year":"2018","unstructured":"Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, et al. DESNT: a poor prognosis category of human prostate cancer. Eur Urol Focus. 2018;4:842\u201350.","journal-title":"Eur Urol Focus"},{"key":"3827_CR24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","volume":"34","author":"C Gerhauser","year":"2018","unstructured":"Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, et al. Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell. 2018;34:996\u20131011.","journal-title":"Cancer Cell"},{"key":"3827_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/cancers10100379","volume":"10","author":"NV Sharma","year":"2018","unstructured":"Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, et al. Identification of the transcription factor relationships associated with androgen deprivation therapy response and metastatic progression in prostate cancer. Cancers (Basel). 2018;10:379.","journal-title":"Cancers (Basel)"},{"key":"3827_CR26","doi-asserted-by":"publisher","first-page":"eaaz3577","DOI":"10.1126\/scitranslmed.aaz3577","volume":"12","author":"SK Subudhi","year":"2020","unstructured":"Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12:eaaz3577.","journal-title":"Sci Transl Med"},{"key":"3827_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48:812-830.e14.","journal-title":"Immunity"},{"key":"3827_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9.","journal-title":"Biomark Res"},{"key":"3827_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell. 2018;173:321-337.e10.","journal-title":"Cell"},{"key":"3827_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(05)17947-1","volume":"365","author":"Y Wang","year":"2005","unstructured":"Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671\u20139.","journal-title":"Lancet"},{"key":"3827_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1755-8794-4-3","volume":"4","author":"C Fan","year":"2011","unstructured":"Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 2011;4:3.","journal-title":"BMC Med Genomics"},{"key":"3827_CR32","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1371\/journal.pbio.0020007","volume":"2","author":"HY Chang","year":"2004","unstructured":"Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2:E7.","journal-title":"PLoS Biol"},{"key":"3827_CR33","doi-asserted-by":"publisher","first-page":"e88309","DOI":"10.1371\/journal.pone.0088309","volume":"9","author":"DM Wolf","year":"2014","unstructured":"Wolf DM, Lenburg ME, Yau C, Boudreau A, Van\u2019t Veer LJ. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS ONE. 2014;9:e88309.","journal-title":"PLoS ONE"},{"key":"3827_CR34","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.21037\/tau-20-1231","volume":"10","author":"J Luan","year":"2021","unstructured":"Luan J, Zhang Q, Song L, Wang Y, Ji C, Cong R, et al. Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy. Transl Androl Urol. 2021;10:1018\u201329.","journal-title":"Transl Androl Urol"},{"key":"3827_CR35","doi-asserted-by":"publisher","first-page":"608369","DOI":"10.3389\/fmolb.2021.608369","volume":"8","author":"G Long","year":"2021","unstructured":"Long G, Ouyang W, Zhang Y, Sun G, Gan J, Hu Z, et al. Identification of a DNA repair gene signature and establishment of a prognostic nomogram predicting biochemical-recurrence-free survival of prostate cancer. Front Mol Biosci. 2021;8:608369.","journal-title":"Front Mol Biosci"},{"key":"3827_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4856","author":"X Wang","year":"2022","unstructured":"Wang X, Lv Z, Xia H, Guo X, Wang J, Wang J, et al. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer. Cancer Med. 2022. https:\/\/doi.org\/10.1002\/cam4.4856","journal-title":"Cancer Med"},{"key":"3827_CR37","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.3892\/ol.2020.11830","volume":"20","author":"X Wu","year":"2020","unstructured":"Wu X, Lv D, Lei M, Cai C, Zhao Z, Eftekhar M, et al. A 10-gene signature as a predictor of biochemical recurrence after radical prostatectomy in patients with prostate cancer and a Gleason score \u22657. Oncol Lett. 2020;20:2906\u201318.","journal-title":"Oncol Lett"},{"key":"3827_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209\u201321.","journal-title":"Cancer Cell"},{"key":"3827_CR39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","volume":"44","author":"CE Barbieri","year":"2012","unstructured":"Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685\u20139.","journal-title":"Nat Genet"},{"key":"3827_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer. Science (80\u2212). 2017;355:84\u20138.","journal-title":"Science (80\u2212)"},{"key":"3827_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","volume":"31","author":"M Blattner","year":"2017","unstructured":"Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR SIGNALING. Cancer Cell. 2017;31:436\u201351.","journal-title":"Cancer Cell"},{"key":"3827_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature20788","volume":"541","author":"M Fraser","year":"2017","unstructured":"Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541:359\u201364.","journal-title":"Nature"},{"key":"3827_CR43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","volume":"79","author":"A Neeb","year":"2021","unstructured":"Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, et al. Advanced prostate cancer with ATM loss: PARP and ATR inhibitors. Eur Urol. 2021;79:200\u201311.","journal-title":"Eur Urol"},{"key":"3827_CR44","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41379-019-0260-6","volume":"32","author":"P Hammarsten","year":"2019","unstructured":"Hammarsten P, Josefsson A, Thysell E, Lundholm M, H\u00e4ggl\u00f6f C, Iglesias-Gato D, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod Pathol. 2019;32:1310\u20139.","journal-title":"Mod Pathol"},{"key":"3827_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jnci\/djy141","volume":"111","author":"SG Zhao","year":"2019","unstructured":"Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, et al. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst. 2019;111:301\u201310.","journal-title":"J Natl Cancer Inst"},{"key":"3827_CR46","doi-asserted-by":"publisher","first-page":"bbaa211","DOI":"10.1093\/bib\/bbaa211","volume":"22","author":"C Zhang","year":"2021","unstructured":"Zhang C, Chen T, Li Z, Liu A, Xu Y, Gao Y, et al. Depiction of tumor stemlike features and underlying relationships with hazard immune infiltrations based on large prostate cancer cohorts. Brief Bioinform. 2021;22:bbaa211.","journal-title":"Brief Bioinform"},{"key":"3827_CR47","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ejca.2004.12.035","volume":"41","author":"DI Quinn","year":"2005","unstructured":"Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858\u201387.","journal-title":"Eur J Cancer"},{"key":"3827_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245\u201355.","journal-title":"Lancet Oncol"},{"key":"3827_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jfma.2019.12.015","volume":"119","author":"YC Lu","year":"2020","unstructured":"Lu YC, Kuo MC, Hong JH, Jaw FS, Huang CY, Cheng JCH, et al. Lower postoperative natural killer cell activity is associated with positive surgical margins after radical prostatectomy. J Formos Med Assoc. 2020;119:1673\u201383.","journal-title":"J Formos Med Assoc"},{"key":"3827_CR50","doi-asserted-by":"publisher","first-page":"14360","DOI":"10.18632\/oncotarget.3965","volume":"6","author":"C Pasero","year":"2015","unstructured":"Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015;6:14360\u201373.","journal-title":"Oncotarget"},{"key":"3827_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2164-8-199","volume":"8","author":"CJ Creighton","year":"2007","unstructured":"Creighton CJ. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics. 2007;8:199.","journal-title":"BMC Genomics"},{"key":"3827_CR52","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/CJI.0000000000000045","volume":"37","author":"N Eir\u00f3","year":"2014","unstructured":"Eir\u00f3 N, Bermudez-Fernandez S, Fernandez-Garcia B, Atienza S, Beridze N, Escaf S, et al. Analysis of the expression of interleukins, interferon \u03b2, and nuclear factor-\u03ba B in prostate cancer and their relationship with biochemical recurrence. J Immunother. 2014;37:366\u201373.","journal-title":"J Immunother"},{"key":"3827_CR53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, Version 2. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17:479\u2013505.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3827_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","volume":"19","author":"E Schaeffer","year":"2021","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, Version 1. 2021. J Natl Compr Cancer Netw. 2021;19:134\u201343.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3827_CR55","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3389\/fonc.2019.01263","volume":"9","author":"A Malik","year":"2019","unstructured":"Malik A, Srinivasan S, Batra J. A new era of prostate cancer precision medicine. Front Oncol. 2019;9:1263.","journal-title":"Front Oncol"},{"key":"3827_CR56","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/jcp.2002.003954","volume":"58","author":"C Hughes","year":"2005","unstructured":"Hughes C, Murphy A, Martin C, Sheils O, O\u2019Leary J. Molecular pathology of prostate cancer. J Clin Pathol. 2005;58:673\u201384.","journal-title":"J Clin Pathol"},{"key":"3827_CR57","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/iju.12571","volume":"21","author":"P Mithal","year":"2014","unstructured":"Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol. 2014;21:1209\u201314.","journal-title":"Int J Urol"},{"key":"3827_CR58","doi-asserted-by":"crossref","unstructured":"Konoshenko MY, Bryzgunova OE, Laktionov PP. miRNAs and androgen deprivation therapy for prostate cancer. Biochim. Biophys. Acta - Rev. Cancer. 2021.","DOI":"10.1016\/j.bbcan.2021.188625"},{"key":"3827_CR59","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41419-020-02973-1","volume":"11","author":"X Long","year":"2020","unstructured":"Long X, Hou H, Wang X, Liu S, Diao T, Lai S, et al. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration. Cell Death Dis. 2020;11:779.","journal-title":"Cell Death Dis"},{"key":"3827_CR60","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","volume":"80","author":"HR Cha","year":"2020","unstructured":"Cha HR, Lee JH, Ponnazhagan S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 2020;80:1615\u201323.","journal-title":"Cancer Res"},{"key":"3827_CR61","doi-asserted-by":"publisher","first-page":"e000642","DOI":"10.1136\/jitc-2020-000642","volume":"8","author":"JN Graff","year":"2020","unstructured":"Graff JN, Beer TM, Alumkal JJ, Slottke RE, Redmond WL, Thomas GV, et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J Immunother Cancer. 2020;8:e000642.","journal-title":"J Immunother Cancer"},{"key":"3827_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","volume":"160","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Gonz\u00e1lez Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, et al. Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61\u201371.","journal-title":"Eur J Cancer"},{"key":"3827_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:1\u201314. https:\/\/doi.org\/10.1186\/s13059-017-1349-1","journal-title":"Genome Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03827-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:08:27Z","timestamp":1678770507000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03827-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03827-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y Liao, Y Xu, T Zhu, W Chen, G Wang, Y Han, and S Cai are employees of Burning Rock Biotech. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}